Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Takayuki TakahamaKoichi AzumaMototsugu ShimokawaMasayuki TakedaHidenobu IshiiTerufumi KatoHaruhiro SaitoHaruko DagaYuko TsuboguchiIsamu OkamotoKohei OtsuboHiroaki AkamatsuShunsuke TeraokaToshiaki TakahashiAkira OnoTatsuo OhiraToshihide YokoyamaKazuko SakaiNobuyuki YamamotoKazuto NishioKazuhiko NakagawaPublished in: Cancer (2020)
The results demonstrate the utility of liquid biopsy for the detection of T790M with the Cobas EGFR Mutation Test v2. Plasma genotyping with this assay is informative for treatment selection in clinical practice when tumor sampling is not feasible.